54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market; Nearly 90% of genetic material used in pharmaceutical research is Caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions.

Abridge powers better care delivery experiences for everyone. Structure, summarize, and get insights on any healthcare conversation — all through Abridge’s medical AI.

Our mission is to enable positive action against climate change by leveraging nature’s most resilient members: microbes. But to accomplish this enormous task we need to find and design the right microbes and deliver them. Growing food is a source of 19% of annual GHG emissions, whereas production (such as cement and plastic) and transportation contribute 31% and 16%, respectively. These activities and emissions can be completely transformed with the right microbes performing specific tasks. Delivering microbes at the vast scale required to enable change has been unsolved. Until Andes.

Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease. The Company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its programs in atopic dermatitis and targeted orphan indications.

Braid Health has built the first frictionless infrastructure for healthcare data and collaboration: FDA-cleared, secure, real-time, modality-agnostic, and AI-augmented. With products in areas of: 1) interoperability and care coordination for IDNs, providers, and patients; 2) collaboration for multidisciplinary conferences and tumor boards; 3) AI-supported radiology software and service; and 4) a reimagined data flywheel for clinical trials and Pharma R&D, our mission is the betterment of patient care.

Character Biosciences (formerly Clover Therapeutics) is a precision medicine platform that is unlocking the patterns of age-related diseases in people of diverse backgrounds. Our mission is to use human genetics to understand what drives diseases so we can discover targeted therapies to more effectively treat patients - many of whom lack any treatment options today. Character partners with patients, providers, payers, and scientists to create deeply-phenotyped patient cohorts to enable clinical genomic research. Our approach integrates genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines.

Checkerspot is a high performance materials company that designs materials at a molecular level. We exist because the world needs new materials designed to perform better but are also less toxic and safer for the environment, and can be biomanufactured at scale. Our Mission is to use the power of biotechnology to expand the palette of molecular building blocks for high performance and sustainable materials. Our Vision is to be the most impactful 21st century materials company by delivering unique, new technologies & materials into the hands of fabricators and designers, the makers that conceive the next generation of high performance products. We do this by optimizing natural microbes to biomanufacture unique structural oils discovered in nature, but not previously accessible commercially.

Cypris Materials is developing a new generation of sustainable color that broadens the color gamut while simplifying manufacturing, application and formulation.

We use science, strategy and creativity to build big businesses that put humanity ahead. Powered by breakthrough biotechnology and human-centered brand innovation, our integrated creation model sets the pace for an ever-changing world.

Dimension Inx is the architect of regenerative microenvironments. Our materials give the body a blueprint to heal itself. We take a materials-centric approach to solving patient needs. By creating structures that emulate the body’s microenvironment, we elicit an immediate regenerative response. We design for biofunctionality and manufacturability. Our platform is highly adaptable and not limited to any single material. Our collaborative studio approach allows us to co-create a lasting advantage by partnering with leading product and R&D organizations. Contact us to accelerate the development of new regenerative solutions today.

Dyno Therapeutics is a Cambridge based, VC-backed biotech startup that uses next-gen DNA technologies and machine learning to engineer Adeno-associated Virus (AAV) capsids for effective delivery of gene therapies.

Elegen is a biotechnology company that develops microfluidic technology. It is driven by a mission to deploy this technology in a new generation of DNA synthesizers aimed at enabling and accelerating biomedical advances. The company was founded in 2017 and led by Dr. Matthew Hill.